Literature DB >> 26721895

Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family.

Anand Pathak1, Katja Seipel2, Alexander Pemov1, Ramita Dewan1, Christina Brown3, Sarangan Ravichandran4, Brian T Luke4, Michael Malasky5, Shalabh Suman5, Meredith Yeager5, Richard A Gatti6, Neil E Caporaso7, John J Mulvihill8, Lynn R Goldin7, Thomas Pabst2, Mary L McMaster7, Douglas R Stewart9.   

Abstract

Familial acute myeloid leukemia is rare and linked to germline mutations in RUNX1, GATA2 or CCAAT/enhancer binding protein-α (CEBPA). We re-evaluated a large family with acute myeloid leukemia originally seen at NIH in 1969. We used whole exome sequencing to study this family, and conducted in silico bioinformatics analysis, protein structural modeling and laboratory experiments to assess the impact of the identified CEBPA Q311P mutation. Unlike most previously identified germline mutations in CEBPA, which were N-terminal frameshift mutations, we identified a novel Q311P variant that was located in the C-terminal bZip domain of C/EBPα. Protein structural modeling suggested that the Q311P mutation alters the ability of the CEBPA dimer to bind DNA. Electrophoretic mobility shift assays showed that the Q311P mu-tant had attenuated binding to DNA, as predicted by the protein modeling. Consistent with these findings, we found that the Q311P mutation has reduced transactivation, consistent with a loss-of-function mutation. From 45 years of follow up, we observed incomplete penetrance (46%) of CEBPA Q311P. This study of a large multi-generational pedigree reveals that a germline mutation in the C-terminal bZip domain can alter the ability of C/EBP-α to bind DNA and reduces transactivation, leading to acute myeloid leukemia. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26721895      PMCID: PMC5004464          DOI: 10.3324/haematol.2015.130799

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  31 in total

Review 1.  Scissors-grip model for DNA recognition by a family of leucine zipper proteins.

Authors:  C R Vinson; P B Sigler; S L McKnight
Journal:  Science       Date:  1989-11-17       Impact factor: 47.728

2.  Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia.

Authors:  G S Sellick; H E Spendlove; D Catovsky; K Pritchard-Jones; R S Houlston
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

3.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  Induction of granulocytic differentiation by 2 pathways.

Authors:  Pu Zhang; Erik Nelson; Hanna S Radomska; Junko Iwasaki-Arai; Koichi Akashi; Alan D Friedman; Daniel G Tenen
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Authors:  Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia A J Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Journal:  Blood       Date:  2010-12-21       Impact factor: 22.113

6.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

7.  CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors.

Authors:  H S Radomska; C S Huettner; P Zhang; T Cheng; D T Scadden; D G Tenen
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

Review 8.  Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature.

Authors:  Juehua Gao; Ryan D Gentzler; Andrew E Timms; Marshall S Horwitz; Olga Frankfurt; Jessica K Altman; LoAnn C Peterson
Journal:  J Hematol Oncol       Date:  2014-04-22       Impact factor: 17.388

9.  Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models.

Authors:  Hashem A Shihab; Julian Gough; David N Cooper; Peter D Stenson; Gary L A Barker; Keith J Edwards; Ian N M Day; Tom R Gaunt
Journal:  Hum Mutat       Date:  2012-11-02       Impact factor: 4.878

10.  Dubowitz syndrome is a complex comprised of multiple, genetically distinct and phenotypically overlapping disorders.

Authors:  Douglas R Stewart; Alexander Pemov; Jennifer J Johnston; Julie C Sapp; Meredith Yeager; Ji He; Joseph F Boland; Laurie Burdett; Christina Brown; Richard A Gatti; Blanche P Alter; Leslie G Biesecker; Sharon A Savage
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

View more
  11 in total

Review 1.  Genomic approaches to accelerate cancer interception.

Authors:  Jennifer Beane; Joshua D Campbell; Julian Lel; Jessica Vick; Avrum Spira
Journal:  Lancet Oncol       Date:  2017-07-26       Impact factor: 41.316

2.  Index case of acute myeloid leukemia in a family harboring a novel CEBPA germ line mutation.

Authors:  Jodi Ram; Gabrielle Flamm; Marlene Balys; Umayal Sivagnanalingam; Paul G Rothberg; Anwar Iqbal; Jason R Myers; Anthony Corbett; John M Ashton; Jason H Mendler
Journal:  Blood Adv       Date:  2017-03-14

Review 3.  Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors:  Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 4.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

Review 5.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

Review 6.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

Review 7.  Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

Authors:  Jeffery M Klco; Charles G Mullighan
Journal:  Nat Rev Cancer       Date:  2020-12-16       Impact factor: 60.716

8.  [Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia].

Authors:  J P Zhang; D Lin; S C Wang; Y Li; Y M Chen; Y Wang; H Wei; Y C Mi; J X Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-12-14

9.  CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition.

Authors:  Meng Liu; Mengbao Du; Jian Yu; Zijun Qian; Yang Gao; Wenjue Pan; Xiujie Zhao; Mowang Wang; Huimin Li; Jiaqi Zheng; Qianshuo Huang; Li-Mengmeng Wang; Haowen Xiao
Journal:  Oncoimmunology       Date:  2022-01-05       Impact factor: 8.110

10.  The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.

Authors:  Ana Rio-Machin; Tom Vulliamy; Nele Hug; Amanda Walne; Kiran Tawana; Shirleny Cardoso; Alicia Ellison; Nikolas Pontikos; Jun Wang; Hemanth Tummala; Ahad Fahad H Al Seraihi; Jenna Alnajar; Findlay Bewicke-Copley; Hannah Armes; Michael Barnett; Adrian Bloor; Csaba Bödör; David Bowen; Pierre Fenaux; Andrew Green; Andrew Hallahan; Henrik Hjorth-Hansen; Upal Hossain; Sally Killick; Sarah Lawson; Mark Layton; Alison M Male; Judith Marsh; Priyanka Mehta; Rogier Mous; Josep F Nomdedéu; Carolyn Owen; Jiri Pavlu; Elspeth M Payne; Rachel E Protheroe; Claude Preudhomme; Nuria Pujol-Moix; Aline Renneville; Nigel Russell; Anand Saggar; Gabriela Sciuccati; David Taussig; Cynthia L Toze; Anne Uyttebroeck; Peter Vandenberghe; Brigitte Schlegelberger; Tim Ripperger; Doris Steinemann; John Wu; Joanne Mason; Paula Page; Susanna Akiki; Kim Reay; Jamie D Cavenagh; Vincent Plagnol; Javier F Caceres; Jude Fitzgibbon; Inderjeet Dokal
Journal:  Nat Commun       Date:  2020-02-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.